NYC Bioscience: Eds & Meds
Session Summary by Jennifer Yoo, Kristy Sundjaja, and Steven Strauss
Center for Economic Transformation
New York City’s academic medical centers, non-profits, and existing base of bioscience enterprise represent a significant asset to developing a broader bioscience cluster, which we also call “Eds & Meds.” Last month, for our kickoff CEO workshop for our Bio (Eds & Meds) NYC 2020 initiative, we convened more than 25 CEOs from New York City’s bioscience sector to discuss the strengths, challenges and future opportunities for the bioscience cluster in NYC. Among the attendees were Jack Lasersohn (General Partner of the Vertical Group, a venture capital firm), Eric Rose (CEO of SIGA Human Bioarmour, an NYC-based biodefense company), Todd Sherer (CEO of the Michael J. Fox Foundation for Parkinson’s Research) and Marc Tessier-Lavigne (President of Rockefeller University).
In a voting exercise, those in attendance rated what they perceive to be the key issues facing NYC, as well as the ways to advance bioscience in the City. We present the key findings below.
NYC’s strengths and challenges
NYC has several advantages that support a strong bioscience cluster, including:
Diversity of the City’s patient population
Robust clinical trials environment
Presence of specialized disease foundations and private philanthropy
Local scientific expertise available for due diligence
Funding for basic and translational research
Nonetheless, global changes are transforming the bioscience landscape. Among the concerns raised during our discussion were:
Funding: The industry faces potential decline in NIH funding, and the venture capital ‘Valley of Death’ is a significant disadvantage for NYC.
Cost structure: Coupled with increasing cost pressures in healthcare, NYC’s cost structure is a disadvantage relative to other clusters.
Talent and innovation: NYC lacks a critical mass of Eds & Meds entrepreneurs, especially since the bioscience cluster needs for both serial entrepreneurs and experienced middle managers for new ventures.
Community support: There is a limited sense of the community’s celebrating entrepreneurship in the life sciences and healthcare.
Coordination: There is room for improved coordination in clinical trials and health IT among academic medical centers.
Progress against the barriers discussed above has been made in recent years, but there is more work to be done. Addressing the remaining barriers and capturing the market opportunities require a concerted, long-term effort. The group discussed some early ideas:
Develop the commercial bioscience sector: Scientists would benefit not only from early-stage funding opportunities, but also from partnerships with entrepreneurs.
Invest in young local talent: Produce NYC’s next generation of Eds & Meds entrepreneurs, particularly through mentorship opportunities.
Defend NYC’s status as a hub of first-rate academic research and medical care: Investments in shared research facilities can be increasingly important, as with health IT tools that decrease the cost of care.
Medical tourism and patient recruitment: Provide additional revenue opportunities for the City’s medical centers.
NYCEDC is committed to improving the economy of NYC and we continue to believe that the life sciences and healthcare sectors represent an important growth opportunity. In the coming months, we will build on the insights gained from this discussion to explore specific opportunities for NYC Eds & Meds cluster. Continuing to work with our knowledge partner Oliver Wyman, we will follow up on these discussion points in a second CEO workshop to be held in early fall.
What are your thoughts? Add your voice to the conversation and post your comments below.